Antiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosin
Open accessAbstract
AIMS: In this study, we evaluated the antiviral activity of subtilosin, a cyclical peptide isolated from Bacillus amyloliquefaciens, against herpes simplex virus type 2 (HSV-2) in cell cultures and we investigated subtilosin mode of action. METHODS AND RESULTS: We determined, using a virus yield inhibition assay, that noncytotoxic concentrations of subtilosin inhibit HSV-2 replication in Vero cell cultures. Subtilosin strongly inhibited extracellular and total virus production even when it was added at 8 h postinfection indicating that not only virus release but also viral particle formation is impeded by the antiviral peptide. Although viral glycoprotein gD level of expression is not affected by the bacteriocin, an altered pattern of gD intracellular localization was detected by immunofluorescence assay in subtilosin-treated culture. On the other hand, at high concentrations, subtilosin displays virucidal action. CONCLUSIONS: Subtilosin displays antiviral and virucidal actions against HSV-2. The target of subtilosin inhibitory effect would be late stages of the viral replicative cycle such as viral glycoprotein intracellular transport. SIGNIFICANCE AND IMPACT OF THE STUDY: Given its antimicrobial activity and its safety for human tissues, subtilosin could represent a valuable alternative to be considered in the development of new microbicide formulations.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The bacteriocin subtilosin, produced by Bacillus species, disrupts late infectious stages of both HSV type 1 and HSV type 2.
“the bacteriocin subtilosin, produced by species of the Bacillus genus, disrupts late infectious stages of both HSV type 1 (Torres et al., 2013) and HSV type 2 (Quintana et al., 2014).”
From Viral Infections, the Microbiome, and Probiotics (2021) · cites this paper as Quintana et al., 2014
Some bacteriocins have been observed to display antiviral activity in addition to antibacterial activity.
“Also, some bacteriocins have been observed to display antiviral activity, in addition to their well-known antibacterial activity (Torres et al., 2013; Quintana et al., 2014).”
From Viral Infections, the Microbiome, and Probiotics (2021) · cites this paper as Quintana et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Rapid colorimetric assay for cell growth and survival
Denizot, F., & Lang, R. (1986) · Journal of Immunological Methods · doi:10.1016/0022-1759(86)90368-6 · Cited by 4,907 · see citing works
Freeman, E. E., Weiss, H. A., Glynn, J. R., Cross, P. L., Whitworth, J. A., & Hayes, R. J. (2006) · AIDS · doi:10.1097/01.aids.0000198081.09337.a7 · Cited by 1,192 · see citing works
Efficacy Results of a Trial of a Herpes Simplex Vaccine
Belshe, R. B., Leone, P. A., Bernstein, D. I., Wald, A., Levin, M. J., Stapleton, J. T., Gorfinkel, I. S., Morrow, R., Ewell, M., Stokes‐Riner, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1103151 · Cited by 507 · see citing works
Babasaki, K., Takao, T., Shimonishi, Y., & Kurahashi, K. (1985) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a135315 · Cited by 259 · see citing works
Sutyak, K. E., Wirawan, R. E., Aroutcheva, A. A., & Chikindas, M. L. (2007) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2007.03626.x · Cited by 207 · see citing works
Self-citationCharacterisation of an antiviral pediocin-like bacteriocin produced by Enterococcus faecium
Todorov, S. D., Wachsman, M. B., Tomè, E., Dousset, X., Destro, M. T., Dicks, L. M. T., Franco, B. D. G. D. M., Vaz‐Velho, M., & Drider, D. (2010) · Food Microbiology · doi:10.1016/j.fm.2010.05.001 · Cited by 189 · see citing works
Self-citationHelicase–Primase Inhibitor Pritelivir for HSV-2 Infection
Wald, A., Corey, L., Timmler, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1301150 · Cited by 176 · see citing works
Férir, G., Petrova, M., Andreï, G., Huskens, D., Hoorelbeke, B., Snoeck, R., Vanderleyden, J., Balzarini, J. M., Bartoschek, S., Brönstrup, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064010 · Cited by 167 · see citing works
Toward global prevention of sexually transmitted infections (STIs): The need for STI vaccines
Gottlieb, S. L., Low, N. N., Newman, L. M., BOLAN, G. A., Kamb, M. L., & Broutet, N. J. N. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.07.087 · Cited by 162 · see citing works
Enterocin CRL35 inhibits late stages of HSV-1 and HSV-2 replication in vitro
Wachsman, M. B., Castilla, V., Holgado, A. P. D. R., Torres, R. A. D., Sesma, F., & Coto, C. E. (2003) · Antiviral Research · doi:10.1016/s0166-3542(02)00099-2 · Cited by 161 · see citing works
Self-citationTodorov, S. D., Wachsman, M. B., Knoetze, H., Meincken, M., & Dicks, L. M. T. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.02.005 · Cited by 144 · see citing works
Self-citationJohnston, C., Saracino, M. R., Kuntz, S., Magaret, A., Selke, S., Huang, M.-L. W., Schiffer, J. T., Koelle, D. M., Corey, L., & Wald, A. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61750-9 · Cited by 126 · see citing works
Torres, N. I., Noll, K. S., Xu, S., Li, J., Huang, Q., Sinko, P. J., Wachsman, M. B., & Chikindas, M. L. (2013) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-012-9123-x · Cited by 122 · see citing works
Management of acyclovir-resistant herpes simplex virus
Chilukuri, S., & Rosén, T. (2003) · Dermatologic Clinics · doi:10.1016/s0733-8635(02)00093-1 · Cited by 119 · see citing works
Towards an understanding of the molecular basis of herpes simplex virus latency
Efstathiou, S., & Preston, C. M. (2005) · Virus Research · doi:10.1016/j.virusres.2005.04.017 · Cited by 108 · see citing works
Spermicidal Activity of the Safe Natural Antimicrobial Peptide Subtilosin
Sutyak, K. E., Anderson, R. A., Dover, S. E., Feathergill, K. A., Aroutcheva, A. A., Faro, S., & Chikindas, M. L. (2008) · Infectious Diseases in Obstetrics and Gynecology · doi:10.1155/2008/540758 · Cited by 88 · see citing works
Self-citationAntiviral activity of enterocin CRL35 against herpesviruses
Wachsman, M. B., Farías, M. E., Takeda, E., Sesma, F. J. M., Holgado, A. P. D. R., de Torres, R. A., & Coto, C. E. (1999) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(99)00078-3 · Cited by 83 · see citing works
Self-citationMarx, R., Stein, T., ENTIAN, K., & Glaser, S. J. (2001) · Journal of Protein Chemistry · doi:10.1023/a:1012562631268 · Cited by 73 · see citing works
Antiinfluenza virus activity of a bacteriocin produced by Lactobacillus delbrueckii
Serkedjieva, J., Danova, S., & Ivanova, I. (2000) · Applied Biochemistry and Biotechnology · doi:10.1385/abab:88:1-3:285 · Cited by 64 · see citing works
Turovskiy, Y., Cheryian, T., Algburi, A., Wirawan, R. E., Takhistov, P., Sinko, P. J., & Chikindas, M. L. (2012) · Infectious Diseases in Obstetrics and Gynecology · doi:10.1155/2012/284762 · Cited by 55 · see citing works
Self-citationMucosal Herpes Immunity and Immunopathology to Ocular and Genital Herpes Simplex Virus Infections
Chentoufi, A. A., & BenMohamed, L. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/149135 · Cited by 50 · see citing works
Noll, K. S., Prichard, M. N., Khaykin, A., Sinko, P. J., & Chikindas, M. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05861-11 · Cited by 48 · see citing works
Self-citationvan Velzen, M., van Loenen, F. B., Meesters, R. J. W., de Graaf, M., Remeijer, L., Luider, T. M., Osterhaus, A. D. M. E., & Verjans, G. M. G. M. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis237 · Cited by 47 · see citing works
Aciclovir‐resistant herpes keratitis
Choong, K., Walker, N. J., Apel, A., & Whitby, M. (2010) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2010.02209.x · Cited by 42 · see citing works
van Kuijk, S. J. A., Noll, K. S., & Chikindas, M. L. (2011) · Letters in Applied Microbiology · doi:10.1111/j.1472-765x.2011.03170.x · Cited by 37 · see citing works
Self-citationFife, K. H., Warren, T. J., Justus, S. E., & Heitman, C. K. (2008) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e31816d1f42 · Cited by 29 · see citing works
Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention
Thurman, A. R., & Doncel, G. F. (2012) · International Journal of STD & AIDS · doi:10.1258/ijsa.2012.011356 · Cited by 27 · see citing works
., S. S., Rasool, S. A., Ahmad, S., Zaidi, S., & ., S. R. (2007) · Research Journal of Microbiology · doi:10.3923/jm.2007.796.806 · Cited by 26 · see citing works
Jarlais, D. C. D., Arasteh, K., McKnight, C. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087993 · Cited by 23 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Viral Infections, the Microbiome, and Probiotics
Harper, A., Vijayakumar, V., Ouwehand, A. C., ter Haar, J., Obis, D., Espadaler, J., Binda, S., Desiraju, S., & Day, R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.596166 · Cited by 177 · see citing works
- Authors
- Quintana, V. M., Torres, N. I., Wachsman, M. B., Sinko, P. J., Castilla, V., & Chikindas, M.
- Affiliations
- Universidad de Buenos Aires (AR)
- Rutgers, The State University of New Jersey (US)
- Corresponding author
- Castilla, V.
- Venue
- Journal of Applied Microbiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-08-23
- Volume
- 117
- Issue
- 5
- Pages
- 1253-1259
- ISSN
- 1364-5072 (ISSN-L)
- PMC
- PMC4198449
- OpenAlex
- W2118212990
- Cited by
- 69
- References
- 29
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 7 · 2023: 8 · 2022: 7 · 2021: 16 · 2020: 9 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 1 · 2015: 2 · 2014: 1
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Applied Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Americanae (AECID Library) (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Rutgers University Community Repository (Rutgers University) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- Universidad de Buenos Aires (20020110100076)
- Bill and Melinda Gates Foundation Grand Challenges Exploration (OPP1025200)
- National Institutes of Health/National Institute of Allergy and Infectious Diseases (1R01AI084137)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
- Health Sciences › Medicine › Epidemiology › Herpesvirus Infections and Treatments
- Physical Sciences › Environmental Science › Ecology › Bacteriophages and microbial interactions
- Keywords
- herpes simplex virus type 2, antiviral activity, virucidal activity, Bacillus amyloliquefaciens, cyclic peptides, bacteriocins, intracellular transport, viral replication inhibition, microbicides
- MeSH terms
- Animals, Antiviral Agents, Bacteriocins, Chlorocebus aethiops, Humans, Peptides, Cyclic, Vero Cells, Herpesvirus 2, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
